The American Association for Cancer Research (AACR) Annual Meeting 2026 opens in San Diego this week, and for anyone working in oncology, drug development, or the broader life sciences investment community, it is the single most data-dense week of the year. The programme will feature more than 100 scientific sessions, and over 7,400 abstracts will be presented, covering everything from first-in-human cell therapy results to AI-driven biomarker discovery. For researchers assessing where their field is heading, clinicians evaluating practice-changing trial data, and investors tracking pipeline assets, the decisions they make in the weeks following AACR are often shaped by what gets presented here.
What is the AACR Annual Meeting 2026 and where does it take place this year?
The AACR Annual Meeting 2026 is being held at the San Diego Convention Center in San Diego, California, running from April 17 to 22, 2026. The event is organised and hosted by the American Association for Cancer Research, the professional body that serves as the organisational backbone of the global cancer research community. The American Association for Cancer Research annual meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. All sessions held in the Convention Center are simultaneously live-streamed to a virtual meeting platform, giving registered attendees who cannot travel to San Diego access to the full scientific programme in real time.
Who governs the AACR and who is leading the 2026 meeting programme?
The AACR currently has more than 62,600 members residing in 143 countries and territories, including laboratory, translational, and clinical researchers, other health care professionals, and cancer advocates, with membership including 342 Fellows of the AACR Academy, of whom 57 are Nobel laureates. Lillian L. Siu serves as President for 2025 to 2026. The 2026 annual meeting programme is led by two co-chairs: Paul S. Mischel of Stanford University, a Fellow of the AACR Academy, and Alice T. Shaw of the Dana-Farber Cancer Institute, newly elected as a Fellow of the AACR Academy. Both chairs bring active clinical and research profiles that shape the sessions they have curated, with Shaw’s background in thoracic oncology and Mischel’s in brain cancer biology reflected across multiple plenary and minisymposium selections.
What are the core scientific themes and plenary sessions at AACR 2026?
The theme for this year’s American Association for Cancer Research meeting is “Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally,” and the 2026 meeting is structured around three core themes that reflect the current state of cancer research. The programme signals a field simultaneously accelerating on multiple fronts: AI integration, next-generation cell therapy, antibody-drug conjugates, RAS-targeted small molecules, and early cancer interception are all major threads running through the week.
The Opening Plenary Session on Sunday, April 19 is titled “Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally” and features Carl H. June of the University of Pennsylvania, Georg E. Winter of the AITHYRA Institute for Biomedical AI in Vienna, Regina Barzilay of the Massachusetts Institute of Technology, and Charles L. Sawyers of Memorial Sloan Kettering Cancer Center. This lineup is deliberately cross-disciplinary, pairing the immunotherapy pioneer who developed CAR T technology with an AI researcher whose work on cancer diagnosis has drawn significant attention outside the laboratory community. Monday, April 20 features a dedicated plenary titled “AI Revolution in Cancer Research,” chaired by Jakob Nicholas Kather of Technische Universität Dresden, with speakers including Jure Leskovec of Stanford University, Faisal Mahmood of Harvard Medical School, and Suchi Saria of Johns Hopkins.
The Saturday opening session preceding the main programme is also substantive. The Discovery Science Plenary on April 18 is titled “The Next Frontier in Minimal Residual Disease: Solid Tumors,” chaired by Maximilian Diehn of Stanford University. Minimal residual disease detection in solid tumours has become one of the more commercially consequential areas of oncology diagnostics, and a dedicated plenary reflects both scientific momentum and investor interest in multi-cancer early detection companies.
What clinical trial and drug pipeline data is being presented at AACR 2026?
For the biopharma and investment community, the most immediate value of AACR lies in its clinical trial programme. The full text of clinical trial and late-breaking abstracts was posted to the online itinerary planner on April 17, 2026, and published as an online supplement to the AACR journal Cancer Research. This release structure means that a significant volume of previously embargoed trial data became publicly available at the start of the meeting, driving the week’s news cycle across oncology media and triggering stock movements in relevant biotech names.
Among the most closely watched sessions is the RAS inhibitor programme from Revolution Medicines. The company announced nine oral and poster presentations at AACR 2026 spanning Phase 1, Phase 1/2, and Phase 3 datasets, with highlights including Phase 1 data for zoldonrasib in KRAS G12D non-small cell lung cancer in a plenary session, and Phase 1/2 daraxonrasib datasets in first-line metastatic pancreatic ductal adenocarcinoma in a minisymposium. A Phase 3 study of daraxonrasib versus docetaxel in previously treated RAS-mutant NSCLC is presented as a late-breaking poster on April 21. RAS-mutant cancers have historically been among the most treatment-resistant tumour types, and plenary-level presentation of Phase 1 data signals that the AACR programme committee regards this class of inhibitors as scientifically mature enough for the broadest possible audience.
CAR T cell therapy for solid tumours is another headline theme. In the Opening Plenary, Carl June of the University of Pennsylvania will present on the evolution of CAR T therapy for solid malignancies, where researchers continue to advance next-generation approaches including dual-target constructs designed for glioblastoma. The shift from haematologic cancers to solid tumours has been a years-long challenge for the CAR T field, and plenary placement of this work reflects progress that researchers across the field will be assessing for translational implications.
Antibody-drug conjugates remain a dominant topic throughout the poster and oral sessions. Presentation titles identify 18 industry ADC projects in the meeting’s poster sessions, including previously unknown programmes and assets where targets are being disclosed for the first time. The most notable is ARC-401 from Araris Biotech, an ADC described as carrying three distinct payloads, with the rationale that multiple payloads may circumvent resistance mechanisms that arise not only against an ADC’s antigen target but also against its cytotoxic agent. Single-payload ADCs also have plenary representation, with clinical data from GSK and Hansoh’s risvutatug rezetecan and CSPC’s SYS6010 both presented in plenary sessions as assets that have entered pivotal development.
Pancreatic cancer science features strongly across multiple sessions. Penn Medicine researchers will present work showing that precancerous cells in the pancreas can be eliminated before they develop into tumours, a finding previously published in Science and now expanded at AACR, covering active RAS inhibition as an interception strategy in mouse models. Though preclinical, this class of finding attracts close attention given the historically poor prognosis for pancreatic cancer detected at advanced stages.
How does AACR compare to other major oncology conferences in the annual calendar?
AACR occupies a distinct position in the oncology conference ecosystem. ASCO, the American Society of Clinical Oncology annual meeting held in June, tends to carry more practice-changing Phase 3 results and attracts a higher proportion of clinical oncologists. AACR, by contrast, has a broader scientific scope, with deeper representation from basic and translational research, early-phase drug data, and methodology sessions. ESMO, the European Society for Medical Oncology congress held in the autumn, similarly focuses on clinical outcomes but carries significant European regulatory and market access context.
What makes AACR distinctive for the pharma and biotech community is its combination of early data readouts and the dedicated Oncology Industry Partnering Event held alongside the main programme. The partnering event is described as the must-attend gathering for the oncology drug development and investment communities, with presentations from major pharmaceutical companies as well as biotech showcase slots, and is available as an in-person only event requiring separate registration from the annual meeting itself. For investors and business development professionals, this adjacent event compresses the deal-making function of the week into a structured format.
The San Antonio Breast Cancer Symposium, held each December, and the ASH annual meeting in haematology carry comparable weight in their respective subspecialties, but neither matches AACR’s breadth across tumour types and research stages.
What is the history of the AACR and how did the annual meeting develop its current scale?
On May 7, 1907, eleven visionary scientists met at the Willard Hotel in Washington, D.C., to develop a scientific organisation to further the investigation and spread the knowledge of cancer, marking the founding of the American Association for Cancer Research, the first and largest professional organisation dedicated to advancing progress against cancer. The association’s growth from that small founding group to a global membership of more than 60,000 across 143 countries tracks almost precisely with the professionalisation of cancer research as a discipline and the expansion of the pharmaceutical industry’s oncology pipeline from the mid-20th century onwards.
AACR’s annual meeting now attracts more than 23,000 participants from around the world and has been described as the main forum to present and discuss cancer-related research, with attendees gathering to discuss over 7,000 abstracts and to hear more than 500 invited presentations on significant discoveries in basic, clinical, and translational cancer research. The meeting’s journal infrastructure also underpins its influence. Cancer Research, the AACR’s flagship publication, is among the most-cited oncology journals globally, and Cancer Discovery, launched in 2011, has become a primary venue for high-impact translational and clinical findings.
What does the 2026 programme tell us about the practical value for attendees and how do participants access sessions?
For researchers and clinicians attending in person or virtually, the 2026 programme structure has introduced one meaningful change from prior years. Educational Sessions and Methods Workshops are available to all attendees as part of their standard meeting registration at no additional cost, providing two days of cross-disciplinary programming before the main scientific sessions begin. In previous years, some educational content carried additional registration charges. This change makes the full breadth of the programme more accessible to early-career researchers and attendees from institutions with limited conference budgets.
All sessions in the Convention Center are live-streamed to the virtual meeting platform, and the AACR Meetings App contains the full text of more than 7,000 abstracts stored locally and accessible without an internet connection. The app allows attendees to search by author, title, and keyword and build a personalised session itinerary, which is a practical necessity given the volume of concurrent programming across a six-day meeting.
The patient advocacy infrastructure at AACR 2026 is notably scaled. AACR received over 400 applications from advocates representing 20 countries for the 2026 Scientist↔Survivor Programme, an international educational initiative that provides cancer survivors and patient advocates with the opportunity to attend scientific sessions, present posters, and network with leading cancer researchers. The programme reflects an institutional commitment at AACR to ensure that basic science findings are contextualised against lived patient experience, which has increasingly become a differentiator from more purely academic conferences.
What are the latest developments at AACR going into the 2026 meeting?
Several structural and thematic shifts define the 2026 edition relative to prior years. The integration of AI into the programme is more explicit than at any previous annual meeting. Beyond the dedicated AI plenary on April 20, multiple sessions across the week address machine learning applications in digital pathology, clinical trial design, and spatial omics. The programme includes a session on deep learning in digital pathology covering morphology to multimodal biomarkers, as well as a session on the AACR Project GENIE data model as a foundation for structured data collection to support precision oncology.
The precision prevention theme is also prominent in a manner that signals a meaningful broadening of the conference’s traditional scope. A plenary session on April 20 is dedicated to “Targeting Stage 0: Precision-Based Prevention,” chaired by Raymond N. Dubois of MUSC Hollings Cancer Center, with speakers from Newcastle University, the University of Washington, UCLA, and Baylor College of Medicine. Prevention research has historically occupied the margins of major oncology conferences relative to treatment data, but its elevation to plenary status at AACR 2026 reflects both scientific maturation and policy pressure on health systems to identify cancer before it becomes invasive.
AACR will also honour leaders from government and the advocacy community with awards for distinguished service in support of cancer research at the 2026 meeting. The associated Biedler Prize for Cancer Journalism is among the awards being announced at the 2026 gathering, signalling continued institutional investment in science communication as a function adjacent to the research enterprise itself.
One contextual pressure relevant to the 2026 meeting’s policy sessions concerns the broader funding environment for cancer research in the United States. Federal funding cuts to the National Institutes of Health and related agencies proposed during the current political cycle have drawn explicit response from AACR, with the organisation publishing commentary through its Cancer Research Catalyst platform ahead of the meeting on why funding continuity matters for oncology progress [VERIFY for current legislative status].
What is the trajectory for the AACR Annual Meeting over the next two to three years?
Future annual meetings are already confirmed: the 2028 meeting will be held at the Ernest N. Morial Convention Center in New Orleans from April 21 to 26, and the 2029 meeting returns to the San Diego Convention Center from April 13 to 18. The alternating pattern between San Diego and other major US convention cities reflects both logistical capacity requirements and a desire to distribute the economic and networking benefit of a 20,000-plus-attendee event across different research clusters.
The integration of AI tools into the scientific programme is likely to deepen over the next two to three years, both as a subject of research presented at the meeting and as an infrastructure layer for how abstracts are searched, sessions are curated, and data is disseminated. The multi-cancer early detection field, which received dedicated session time in 2026, is expected to yield significant trial results through 2027 and 2028 that will likely shape the clinical trial plenary content at those gatherings. The antibody-drug conjugate pipeline, now featuring triple-payload constructs and novel target combinations in preclinical and early clinical stages at the 2026 meeting, is positioned to generate regulatory submissions and approval-stage data by the 2028 cycle.
For the pharma industry, AACR’s Oncology Industry Partnering Event will continue to function as a parallel deal-making forum, with the expectation that RAS inhibitors, next-generation CAR T constructs, and AI-enabled diagnostics will remain the most commercially active categories in the near-term conference agenda.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
